Generate Biomedicines, Inc.

Item 7.01 Regulation FD Disclosure. On August 25, 2026, draft copies of three posters submitted by Generate Biomedicines, Inc. (the “Company”) and accepted for presentation at the European Respiratory Society Congress 2026 (“ERS”), scheduled for September 5-9, 2026, were inadvertently made publicly available via the ERS website prior to the expiration of the applicable embargo, which the Company believed would run until 6:01 p.m., Eastern time, on September 7, 2026. The draft posters include results of ongoing clinical trials sponsored by the Company and are entitled: • “GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients”; • “SOLAIRIA-1 & SOLAIRIA-2: Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma”; and • “GB-0895, a High-Affinity Anti-TSLP Antibody, Demonstrates Potent and Sustained Pharmacological Activity in Adults with COPD.” As a precautionary measure, the Company is providing the final posters attached hereto as Exhibit 99.1, which include the information that was furnished to ERS. The information included under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.